CD34+ Transplants for Leukemia and Lymphoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-74
SponsorGuenther Koehne
About this trial
This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy (cancer) or blood disorder.
Eligibility criteria
Qualifiers
AML in 1st remission - for patients who is AML does not have 'good risk' cytogenetic features (i.e. t8:21, t 15: 17, inv16).
Secondary AML in 1st remission
AML in 1st relapse or 2nd remission
ALL/CLL in patient remission clinical or molecular features indicating a high risk for relapse; or ALL/CLL 2nd remission
Disqualifiers
Female patients who are pregnant or breast-feeding
Active viral, bacterial or fungal infection
Patient seropositive for HIV-I /II; HTLV -I /II
Presence of leukemia in the CNS
Trial design
Treatments tested in this trial
- Total Body Irradiation (TBI)
- Thiotepa
- Cyclophosphamide
- Busulfan
- Melphalan
- Fludarabine
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Guenther Koehne
Lead sponsor
Baptist Health South Florida
Sponsor institution
Source ClinicalTrials.gov